A Phase 3 interventional study of Denosumab and Placebo in Osteoporosis, Postmenopausal, sponsored by GlaxoSmithKline. Completed at 8 sites in China. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-10-31.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 17 in phase 3, and was the 16th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 60 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 486 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 7 studies filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.
The aim of this Phase III, randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of denosumab (DMAb) in Chinese postmenopausal women with osteoporosis at increased risk of fracture. The study design consists of two phases: Screening and 12-month Double-Blind treatment phase. Following the Screening phase, all eligible subjects will be randomized to receive Double-Blind DMAb (60 mg) or Placebo study medication in a 3:1 ratio. DMAb 60 mg and placebo will be administered as a single subcutaneous (SC) injection at the beginning of the Double-Blind phase and at 6 months following the initial dose. All subjects will receive daily supplementation of oral elemental calcium (at least 600 mg) and vitamin D (at least 400 International Units [IU]). The primary objective is to determine the effects of DMAb compared to placebo with respect to mean percent change in BMD at the lumbar spine, as measured by dual-energy x-ray absorptiometry (DXA), from Baseline to Month 12. Secondary objectives include the evaluation between the DMAb and placebo treatment groups: change in BMD: at the lumbar spine (Month 6), total hip (Months 6 and 12), femoral neck (Months 6 and 12) and trochanter (Months 6 and 12); and serum biomarkers of bone formation and resorption (Months 6 and 12). Clinical safety of denosumab will also be assessed in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
history of fracture parental history of hip fracture increased bone turnover rate at screening (s-CTX >1.0 SD above the mean in healthy premenopausal women) low body weight (≤19kg/m2) elderly (age≥70y) current smoker
Exclusion Criteria:
Any metabolic bone disease, e.g., osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings.
Paget's disease Cushing's disease Hyperprolactinemia
If TSH level is below normal range, subject is not eligible for the study. If TSH level is elevated (>5.5 μIU/mL and ≤10.0 μIU/mL), serum T4 should be measured.
If serum T4 is within normal range, subject is eligible. If serum T4 is outside of normal range, subject is not eligible for the study. If TSH level is > 10.0 μIU/mL, subject is not eligible.
Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5years.
Cirrhosis of the liver Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Chronic stable and C are acceptable if the subject otherwise meets study entry criteria (e.g., presence of hepatitis B surface antigen or positive test result within 3 months of Screening).
Any disorder that compromises the ability of the subject to give written or to comply with study procedures.
Any physical or psychiatric disorder which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results.
Known to have tested positive for (HIV).
Concomitant Medications:
If used for ≥3 years cumulatively, subject is ineligible.
If used for >3-months but \<3 years cumulatively:
If the last dose was \<1 year before enrolment, subject is ineligible. If the last dose was ≥1 year before enrolment, subject is eligible. If used ≤3 months, cumulatively, subject is eligible.
Parathyroid hormone (PTH) or PTH derivatives, e.g., teriparatide. Anabolic steroids or testosterone. Glucocorticosteroids (>5 mg prednisone equivalent per day for more than 10 days).
Systemic hormone replacement therapy. Selective estrogen receptor modulators (SERMs), e.g., raloxifene Tibolone. Calcitonin. Calcitriol or vitamin D derivatives. Other bone active drugs including anti-convulsives (except benzodiazepines) and heparin.
Chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin-releasing hormone agonists.
Serum (AST) ≥2.0 x (ULN). Serum alanine aminotransferase (ALT) ≥2.0 x ULN. Alkaline phosphatase and ≥1.5 x ULN (isolated bilirubin ≥1.5 ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%.
Less than two lumbar vertebrae evaluable for DXA measurements. Height, weight, or girth which may preclude accurate DXA measurements.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
injection
Drug: Denosumab · Dietary Supplement: Elemental Calcium · Dietary Supplement: Vitamin D
injection
Drug: Placebo · Dietary Supplement: Elemental Calcium · Dietary Supplement: Vitamin D
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12
Bone mineral density (BMD) is the amount of bone mineral in bone tissue. BMD scan was done using dual energy x-ray absorptiometry (DXA). It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calcuated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. The analysis was performed by Analysis of Covariance (ANCOVA) model adjusted for treatment, region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as Baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the Last Observation Carried Forward (LOCF), provided the assessment was taken on or after at least one month on-therapy.
Time frame: Baseline and Month 12
Percent Change From Baseline in BMD at the Lumbar Spine at Month 6
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
Time frame: Baseline and Month 6
Percent Change From Baseline in BMD at the Total Hip at Month 6
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
Time frame: Baseline and Month 6
Percent Change From Baseline in BMD at the Femoral Neck at Month 6
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
Time frame: Baseline and Month 6
Percent Change From Baseline in BMD at the Trochanter at Month 6
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
Time frame: Baseline and Month 6
Percent Change From Baseline in BMD at the Total Hip at Month 12
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
Time frame: Baseline and Month 12
Percent Change From Baseline in BMD at the Femoral Neck at Month 12
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
Time frame: Baseline and Month 12
Percent Change From Baseline in BMD at the Trochanter at Month 12
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
Time frame: Baseline and Month 12
Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline to Month 6 and Month 12
s-CTX is biomarker of bone resorption and formation. s-CTX was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in s-CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.
Time frame: Baseline, Month 6 and Month 12
Percent Change in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline to Month 6 and Month 12
s-PINP is biomarker of bone resorption and formation. s-PINP was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in serum CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 1, Month 3, Month 6, and Month 12
Baseline value was obtained at Randomization (Visit 3). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Change from Baseline in SBP and DBP was assessed at Baseline, Month 1, Month 3, Month 6, and Month 12.
Time frame: Baseline, Month 1, Month 3, Month 6 and Month 12
Change From Baseline in Heart Rate at Month 1, Month 3, Month 6, and Month 12
Baseline value was obtained at Randomization (Visit 3). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Change from Baseline in heart rate was assessed at Baseline, Month 1, Month 3, Month 6 and Month 12.
Time frame: Baseline, Month 1, Month 3, Month 6 and Month 12
Change From Baseline in Alanine Amino Transferase, Alkaline Phosphatase, Aspartate Amino Transferase, and Gamma Glutamyl Transferase at Month 1, Month 6 and Month 12
Baseline values were obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Alanine amino transferase, alkaline phosphatase, aspartate amino transferase, and gamma glutamyl transferase were assessed at Baseline, Month 1, Month 6 and Month 12.
Time frame: Baseline, Month 1, Month 6, and Month 12
Change From Baseline in Creatine Kinase, Lactate Dehydrogenase at Month 6 and Month 12.
Baseline values was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Creatine kinase and lactate dehydrogenase were assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Albumin at Month 1, Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Albumin was assessed at Baseline, Month 1, Month 6 and Month 12.
Time frame: Baseline, Month 1, Month 6 and Month 12.
Change From Baseline in Globulin at Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at indicated visit minus the Baseline value. Blood samples were collected for measurement. Globulin was assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Hemoglobin and Total Protein at Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at indicated visit minus the Baseline value. Blood samples were collected for measurement. Hemoglobin and total protein were assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils-total Absolute Neutrophil Count (ANC), White Blood Cell Count at Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils-total ANC and white blood cell count were assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Calcium (Corrected), Calcium at Month 1, Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Calcium (corrected) and calcium were assessed at Baseline, Month 1, Month 6 and Month 12.
Time frame: Baseline, Month 1, Month 6 and Month 12.
Change From Baseline in Chloride, Cholesterol, Glucose, Magnesium, Inorganic Phosphorous, Potassium, Sodium, Triglycerides, Urea/Blood Urea Nitrogen (BUN) at Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Chloride, cholesterol, glucose, magnesium, inorganic phosphorous, potassium, sodium, triglycerides and urea/BUN were assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Direct Bilirubin, Total Bilirubin at Month 1, Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Direct bilirubin and total bilirubin were assessed at Baseline, Month 1, Month 6 and Month 12.
Time frame: Baseline, Month 1, Month 6 and Month 12
Change From Baseline in Creatinine and Uric Acid at Month 6 and Month 12
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Creatinine and uric acid were assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Hematocrit at Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Hematocrit was assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12.
Change From Baseline in Mean Corpuscle Hemoglobin at Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Mean corpuscle hemoglobin was assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12.
Change From Baseline in Mean Corpuscle Volume at Month 6 and Month 12.
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Mean corpuscle volume was assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Red Blood Cell Count at Month 6 and Month 12
Baseline value was obtained at screening (visit 2). If missing, the most recent non-missing value was used. Change in baseline value was assessed as: Value at Indicated visit minus Baseline value. Blood samples were collected for measurement. Red blood cell count was assessed at Baseline, Month 6 and Month 12.
Time frame: Baseline, Month 6 and Month 12
Number of Participants With Confirmed Anti-denosumab Antibody Formation at Baseline and Month 12
Anti-denosumab antibody formation was assessed at Baseline (Visit 3) and Month 12. Binding antibody and neutralizing antibody assays were used to assess number of participants with anti-denosumab antibody.
Time frame: Baseline and Month 12
Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (Non-fatal Serious Adverse Events and Fatal Serious Adverse Events)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or other events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcome listed above, liver injury and impaired liver function and grade 4 laboratory abnormalities. Number of participants with any AEs, serious non-fatal AEs, serious fatal AEs have been presented.
Time frame: From start of IP through the Study Phase (6 months post-dose) (assessed up to 12 months)
The study design consists of two phases: Screening Phase and 12-month Double-blind Treatment Phase. The Screening Phase was to last up to a maximum of 2.5 months, which was followed by a 12-month Double-blind Treatment Phase. The total participation time in the study was approximately 14.5 months.
| Milestone | Denosumab 60 mg | Placebo |
|---|---|---|
| Started | 365 | 119 |
| Completed | 340 | 112 |
| Not completed | 25 | 7 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Protocol violation | 3 | 0 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Withdrawal by subject | 16 | 4 |
Bone mineral density (BMD) is the amount of bone mineral in bone tissue. BMD scan was done using dual energy x-ray absorptiometry (DXA). It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calcuated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. The analysis was performed by Analysis of Covariance (ANCOVA) model adjusted for treatment, region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as Baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the Last Observation Carried Forward (LOCF), provided the assessment was taken on or after at least one month on-therapy.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12 | 5.22 ± 0.274 | 0.79 ± 0.391 |
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in BMD at the Lumbar Spine at Month 6 | 3.77 ± 0.273 | 0.57 ± 0.390 |
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in BMD at the Total Hip at Month 6 | 2.36 ± 0.193 | 0.11 ± 0.279 |
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in BMD at the Femoral Neck at Month 6 | 1.91 ± 0.219 | 0.32 ± 0.315 |
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in BMD at the Trochanter at Month 6 | 2.76 ± 0.344 | -0.59 ± 0.498 |
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in BMD at the Total Hip at Month 12 | 3.03 ± 0.202 | -0.28 ± 0.293 |
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in BMD at the Femoral Neck at Month 12 | 2.77 ± 0.233 | 0.16 ± 0.337 |
BMD is the amount of bone mineral in bone tissue. BMD scan was done using DXA. It is used to identify osteoporosis, determine risk for fractures, and measure response to osteoporosis treatment. The percentage change from Baseline for BMD was calculated as the value at the indicated time point minus the Baseline value multiplied by 100 and divided by the Baseline value. ANCOVA model adjusted for treatment, center/region and Baseline BMD for the skeletal site under consideration as a continuous covariate for assessment. Region and treatment by region interaction was included in the model. Screening visit was considered as baseline for BMD. For participants who withdrew early, the missing BMD assessments was estimated by the LOCF, provided the assessment was taken on or after at least one month on-therapy.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in BMD at the Trochanter at Month 12 | 3.88 ± 0.356 | -0.83 ± 0.517 |
s-CTX is biomarker of bone resorption and formation. s-CTX was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in s-CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| s-CTX, Month 6, n=353, 117 | -79.20 (-86.80 to -66.45) | -19.35 (-35.97 to -2.74) |
| s-CTX, Month 12, n=335, 108 | -64.51 (-77.29 to -38.52) | -5.94 (-29.52 to 16.67) |
s-PINP is biomarker of bone resorption and formation. s-PINP was assessed during Screening, Month 6 and Month 12 in the Double-blind Treatment Phase. The value during Screening was considered as the Baseline value. Percent change from Baseline was assessed as the value at the indicated visit minus the Baseline value divided by the Baseline value x 100. A two-sided Wilcoxon rank sum test was used to compare percent change in serum CTX. Between group inferences is presented by p-values, Hodges-Lehmann estimates along with 95% confidence intervals.
| Percentage change | Denosumab 60 mg | Placebo |
|---|---|---|
| s-PINP, Month 6, n=352, 117 | -73.12 (-81.03 to -62.81) | -12.37 (-29.58 to 4.37) |
| s-PINP, Month 12, n=335, 108 | -66.14 (-76.04 to -50.75) | -14.83 (-27.84 to 11.26) |
Baseline value was obtained at Randomization (Visit 3). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Change from Baseline in SBP and DBP was assessed at Baseline, Month 1, Month 3, Month 6, and Month 12.
| Millimeters of mercury (mmHg) | Denosumab 60 mg | Placebo |
|---|---|---|
| SBP, Month 1, n = 365, 117 | -1.8 ± 11.01 | -1.3 ± 11.89 |
| SBP, Month 3, n = 362, 117 | -3.4 ± 12.62 | -0.5 ± 12.16 |
| SBP, Month 6, n = 350, 114 | 0.1 ± 12.76 | 1.5 ± 13.25 |
| SBP, Month 12, n = 342, 110 | -0.5 ± 11.83 | -0.1 ± 11.69 |
| DBP, Month 1, n = 365, 117 | 0.0 ± 6.95 | 0.6 ± 7.58 |
| DBP, Month 3, n = 362, 117 | -1.5 ± 7.70 | 0.2 ± 6.50 |
| DBP, Month 6, n = 350, 114 | -0.3 ± 7.67 | 1.1 ± 8.34 |
| DBP, Month 12, n = 342, 110 | 0.2 ± 7.63 | 1.2 ± 7.75 |
Baseline value was obtained at Randomization (Visit 3). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Change from Baseline in heart rate was assessed at Baseline, Month 1, Month 3, Month 6 and Month 12.
| Beats per minute | Denosumab 60 mg | Placebo |
|---|---|---|
| Heart Rate, Month 1, n = 365, 117 | -0.8 ± 6.88 | -2.1 ± 7.51 |
| Heart Rate, Month 3, n = 362, 117 | 1.2 ± 10.28 | 0.2 ± 9.08 |
| Heart Rate, Month 6, n = 350, 114 | -0.4 ± 8.23 | -1.3 ± 9.01 |
| Heart Rate, Month 12, n = 342, 110 | -0.9 ± 7.55 | 0.1 ± 10.48 |
Baseline values were obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Alanine amino transferase, alkaline phosphatase, aspartate amino transferase, and gamma glutamyl transferase were assessed at Baseline, Month 1, Month 6 and Month 12.
| International unit per liter (IU/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Alanine Amino Transferase, Month 1, n = 365, 117 | 0.2 ± 6.27 | -0.1 ± 5.91 |
| Alanine Amino Transferase, Month 6, n = 350, 114 | 1.9 ± 9.00 | 0.7 ± 7.19 |
| Alanine Amino Transferase, Month 12, n = 340, 109 | 1.5 ± 12.49 | 0.2 ± 8.45 |
| Alkaline Phosphatase, Month 1, n = 365, 117 | -3.3 ± 11.00 | -3.2 ± 10.03 |
| Alkaline Phosphatase, Month 6, n = 350, 114 | -21.0 ± 17.20 | -1.2 ± 11.43 |
| Alkaline Phosphatase, Month 12, n = 340, 109 | -23.4 ± 17.36 | -5.3 ± 11.06 |
| Aspartate Amino Transferase, Month 1, n = 365, 117 | -0.1 ± 4.34 | -0.4 ± 4.41 |
| Aspartate Amino Transferase, Month 6, n = 350, 114 | 1.2 ± 7.84 | 0.2 ± 5.28 |
| Aspartate Amino Transferase,Month 12, n = 340, 109 | 0.1 ± 7.41 | -0.8 ± 5.94 |
| Gamma Glutamyl Transferase, Month 1, n = 365, 117 | 0.2 ± 11.52 | -0.6 ± 5.82 |
| Gamma Glutamyl Transferase, Month 6, n = 350, 114 | 0.1 ± 11.22 | -0.1 ± 6.44 |
| Gamma Glutamyl Transferase, Month 12, n = 340, 109 | -0.9 ± 9.96 | 0.3 ± 10.09 |
Baseline values was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Creatine kinase and lactate dehydrogenase were assessed at Baseline, Month 6 and Month 12.
| International unit per liter (IU/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Creatine Kinase, Month 6, n = 350, 114 | -3.7 ± 43.41 | -3.7 ± 31.64 |
| Creatine Kinase, Month 12, n = 340, 109 | -2.6 ± 53.83 | -0.3 ± 38.58 |
| Lactate Dehydrogenase, Month 6, n = 350, 114 | -3.4 ± 19.62 | -5.6 ± 19.60 |
| Lactate Dehydrogenase, Month 12, n = 340, 109 | -2.2 ± 18.50 | -4.0 ± 23.16 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Albumin was assessed at Baseline, Month 1, Month 6 and Month 12.
| Gram per liter (G/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Albumin, Month 1, n = 365, 117 | -0.6 ± 1.93 | -0.7 ± 1.75 |
| Albumin, Month 6, n = 350, 114 | 0.7 ± 1.96 | 0.5 ± 2.09 |
| Albumin, Month 12, n = 340, 109 | 0.2 ± 1.82 | 0.1 ± 2.11 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at indicated visit minus the Baseline value. Blood samples were collected for measurement. Globulin was assessed at Baseline, Month 6 and Month 12.
| Grams per liter (G/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Globulin, Month 6, n = 350, 114 | -0.3 ± 2.29 | -0.2 ± 2.35 |
| Globulin, Month 12, n = 340, 109 | -0.5 ± 2.57 | -0.4 ± 2.78 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at indicated visit minus the Baseline value. Blood samples were collected for measurement. Hemoglobin and total protein were assessed at Baseline, Month 6 and Month 12.
| Grams per liter (G/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Hemoglobin, Month 6, n = 346, 113 | 2.3 ± 5.33 | 1.9 ± 5.54 |
| Hemoglobin, Month 12, n = 339, 109 | 0.2 ± 6.12 | 0.7 ± 6.52 |
| Total Protein, Month 6, n = 350, 114 | 0.4 ± 3.30 | 0.3 ± 3.34 |
| Total Protein, Month 12, n = 340, 109 | -0.2 ± 3.57 | -0.3 ± 3.60 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils-total ANC and white blood cell count were assessed at Baseline, Month 6 and Month 12.
| Giga per liter (GI/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Basophils, Month 6, n = 346, 113 | -0.002 ± 0.0180 | -0.001 ± 0.0180 |
| Basophils, Month 12, n = 339, 109 | -0.001 ± 0.0160 | -0.003 ± 0.0183 |
| Eosinophils, Month 6, n = 346, 113 | 0.025 ± 0.1402 | 0.013 ± 0.1240 |
| Eosinophils, Month 12, n = 339, 109 | -0.001 ± 0.1530 | 0.006 ± 0.1382 |
| Lymphocytes, Month 6, n = 346, 113 | 0.011 ± 0.3658 | -0.020 ± 0.3513 |
| Lymphocytes, Month 12, n = 339, 109 | -0.064 ± 0.3689 | -0.082 ± 0.3584 |
| Monocytes, Month 6, n = 346, 113 | 0.042 ± 0.0999 | 0.035 ± 0.0868 |
| Monocytes, Month 12, n = 339, 109 | -0.007 ± 0.1002 | -0.004 ± 0.0800 |
| Platelet count, Month 6, n = 345, 113 | 3.0 ± 30.49 | -0.1 ± 24.08 |
| Platelet count, Month 12, n = 337, 109 | -6.8 ± 26.66 | -3.6 ± 30.82 |
| Total ANC, Month 6, n = 346, 113 | 0.153 ± 1.0436 | -0.002 ± 0.8814 |
| Total ANC, Month 12, n = 339, 109 | -0.071 ± 0.9412 | -0.119 ± 0.9691 |
| White Blood Cell count, Month 6, n = 346, 113 | 0.23 ± 1.166 | 0.02 ± 1.036 |
| White Blood Cell count, Month 12, n = 339, 109 | -0.14 ± 1.083 | -0.20 ± 1.164 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Calcium (corrected) and calcium were assessed at Baseline, Month 1, Month 6 and Month 12.
| Millimoles per liter (mmol/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Calcium (corrected), Month 1, n = 365, 117 | -0.063 ± 0.0740 | 0.000 ± 0.0505 |
| Calcium (corrected), Month 6, n = 350, 114 | -0.020 ± 0.0704 | -0.001 ± 0.0537 |
| Calcium (corrected), Month 12, n = 340, 109 | -0.002 ± 0.0680 | -0.001 ± 0.0488 |
| Calcium, Month 1, n = 365, 117 | -0.074 ± 0.0906 | -0.014 ± 0.0614 |
| Calcium, Month 6, n = 350, 114 | -0.006 ± 0.0809 | 0.009 ± 0.0703 |
| Calcium, Month 12, n = 340, 109 | 0.002 ± 0.0807 | 0.001 ± 0.0648 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Chloride, cholesterol, glucose, magnesium, inorganic phosphorous, potassium, sodium, triglycerides and urea/BUN were assessed at Baseline, Month 6 and Month 12.
| Millimoles per liter (mmol/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Chloride, Month 6, n = 350, 114 | -0.9 ± 2.48 | -0.7 ± 2.37 |
| Chloride, Month 12, n = 340, 109 | 0.4 ± 2.17 | 0.6 ± 2.34 |
| Cholesterol, Month 6, n = 350, 114 | 0.039 ± 0.7626 | 0.057 ± 0.7837 |
| Cholesterol, Month 12, n = 340, 109 | 0.047 ± 0.8909 | 0.058 ± 0.7889 |
| Glucose, Month 6, n = 350, 114 | 0.12 ± 0.882 | 0.04 ± 1.052 |
| Glucose, Month 12, n = 340, 109 | 0.16 ± 0.124 | -0.07 ± 0.752 |
| Magnesium, Month 6, n = 350, 114 | 0.003 ± 0.0523 | -0.002 ± 0.0547 |
| Magnesium, Month 12, n = 340, 109 | 0.013 ± 0.0485 | 0.012 ± 0.0572 |
| Phosphorus, inorganic, Month 6, n = 350, 114 | -0.082 ± 0.1440 | -0.030 ± 0.1353 |
| Phosphorus, inorganic, Month 12, n = 340, 109 | -0.063 ± 0.1520 | -0.028 ± 0.1304 |
| Potassium, Month 6, n = 350, 114 | 0.00 ± 0.328 | 0.02 ± 0.294 |
| Potassium, Month 12, n = 340, 109 | 0.01 ± 0.300 | -0.01 ± 0.294 |
| Sodium, Month 6, n = 350, 114 | -0.8 ± 1.94 | -0.4 ± 2.24 |
| Sodium, Month 12, n = 340, 109 | -1.3 ± 1.93 | -0.7 ± 1.76 |
| Triglycerides, Month 6, n = 350, 114 | -0.082 ± 0.7604 | -0.000 ± 0.6753 |
| Triglycerides, Month 12, n = 340, 109 | -0.014 ± 0.9367 | -0.029 ± 0.7489 |
| Urea/BUN, Month 6, n = 350, 114 | -0.18 ± 1.045 | -0.35 ± 1.288 |
| Urea/BUN, Month 12, n = 340, 109 | 0.04 ± 1.124 | 0.01 ± 1.466 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Direct bilirubin and total bilirubin were assessed at Baseline, Month 1, Month 6 and Month 12.
| Micromoles per liter (UMOL/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Direct Bilirubin, Month 1, n = 365, 117 | -0.1 ± 0.67 | 0.1 ± 0.52 |
| Direct Bilirubin, Month 6, n = 350, 114 | 0.0 ± 0.72 | 0.1 ± 0.66 |
| Direct Bilirubin, Month 12, n = 340, 109 | 0.1 ± 0.67 | 0.2 ± 0.68 |
| Total Bilirubin, Month 1, n = 365, 117 | -0.3 ± 2.83 | 0.2 ± 2.61 |
| Total Bilirubin, Month 6, n = 350, 114 | 0.1 ± 2.91 | 0.2 ± 2.66 |
| Total Bilirubin, Month 12, n = 340, 109 | 0.3 ± 2.98 | 0.2 ± 2.80 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Creatinine and uric acid were assessed at Baseline, Month 6 and Month 12.
| Micromoles per liter (UMOL/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Creatinine, Month 6, n = 350, 114 | -0.47 ± 5.067 | -0.90 ± 5.611 |
| Creatinine, Month 12, n = 340, 109 | -0.18 ± 5.116 | -0.30 ± 6.185 |
| Uric acid, Month 6, n = 350, 114 | -8.9 ± 48.33 | -8.9 ± 48.58 |
| Uric acid, Month 12, n = 340, 109 | -6.7 ± 49.84 | -2.7 ± 44.85 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Hematocrit was assessed at Baseline, Month 6 and Month 12.
| Ratio | Denosumab 60 mg | Placebo |
|---|---|---|
| Hematocrit, Month 6, n = 346, 113 | 0.0024 ± 0.01612 | 0.0012 ± 0.01662 |
| Hematocrit, Month 12, n = 339, 109 | 0.0064 ± 0.01884 | 0.0079 ± 0.01926 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in Baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Mean corpuscle hemoglobin was assessed at Baseline, Month 6 and Month 12.
| Picograms (PG) | Denosumab 60 mg | Placebo |
|---|---|---|
| Mean Corpuscle Hemoglobin, Month 6, n = 346, 113 | 0.22 ± 0.599 | 0.18 ± 0.561 |
| Mean Corpuscle Hemoglobin, Month 12, n = 339, 109 | -0.31 ± 0.691 | -0.38 ± 0.600 |
Baseline value was obtained at Screening (Visit 2). If missing, the most recent non-missing value was used. Change in baseline value was assessed as the value at the indicated visit minus the Baseline value. Blood samples were collected for measurement. Mean corpuscle volume was assessed at Baseline, Month 6 and Month 12.
| Femtoliter (FL) | Denosumab 60 mg | Placebo |
|---|---|---|
| Mean Corpuscle Volume, Month 6, n = 346, 113 | -0.4 ± 1.77 | -0.5 ± 2.17 |
| Mean Corpuscle Volume, Month 12, n = 339, 109 | 0.4 ± 2.01 | 0.3 ± 1.77 |
Baseline value was obtained at screening (visit 2). If missing, the most recent non-missing value was used. Change in baseline value was assessed as: Value at Indicated visit minus Baseline value. Blood samples were collected for measurement. Red blood cell count was assessed at Baseline, Month 6 and Month 12.
| Trillion cells per liter (TI/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Red Blood Cell count, Month 6, n = 346, 113 | 0.04 ± 0.180 | 0.04 ± 0.170 |
| Red Blood Cell count, Month 12, n = 339, 109 | 0.05 ± 0.203 | 0.07 ± 0.200 |
Anti-denosumab antibody formation was assessed at Baseline (Visit 3) and Month 12. Binding antibody and neutralizing antibody assays were used to assess number of participants with anti-denosumab antibody.
| Participants | Denosumab 60 mg | Placebo |
|---|---|---|
| Binding antibody detection, Baseline, n = 15, 3 | 0 | 0 |
| Binding antibody detection, Month 12, n = 29, 3 | 1 | 0 |
| Neutralising antibody detection,Month 12, n = 1,0 | 0 | 0 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or other events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcome listed above, liver injury and impaired liver function and grade 4 laboratory abnormalities. Number of participants with any AEs, serious non-fatal AEs, serious fatal AEs have been presented.
| Participants | Denosumab 60 mg | Placebo |
|---|---|---|
| Any AEs | 174 | 63 |
| Any Serious Non-Fatal AEs | 9 | 3 |
| Any Serious Fatal AEs | 2 | 0 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of IP through the Study Phase (6 months post-dose) (assessed up to 12 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab 60mg | — | 11/367 (3%) | 43/367 (11.7%) |
| Placebo | — | 3/117 (2.6%) | 24/117 (20.5%) |
| Event | Denosumab 60mg | Placebo |
|---|---|---|
| Any eventCardiac disorders | 1/367 | 2/117 |
| Any eventInjury, poisoning and procedural complications | 3/367 | 1/117 |
| Humerus fractureInjury, poisoning and procedural complications | 0/367 | 1/117 |
| Angina unstableCardiac disorders | 0/367 | 1/117 |
| ArrhythmiaCardiac disorders | 0/367 | 1/117 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/367 | 1/117 |
| Myocardial infarctionCardiac disorders | 0/367 | 1/117 |
| Any eventNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/367 | 0/117 |
| Femoral neck fractureInjury, poisoning and procedural complications | 2/367 | 0/117 |
| Any eventInfections and infestations | 2/367 | 0/117 |
| Event | Denosumab 60mg | Placebo |
|---|---|---|
| Blood cholesterol increasedInvestigations | 19/367 | 11/117 |
| ArthralgiaInvestigations | 24/367 | 9/117 |
| Bone density decreasedInvestigations | 2/367 | 6/117 |
| Age, Continuous(Years) | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|
| Mean | 68.9 ± 6.10 | 69.6 ± 5.75 | 69.0 ± 6.02 |
| Sex: Female, Male(Participants) | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|
| Female | 365 | 119 | 484 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|
| Asian - East Asian Heritage | 365 | 119 | 484 |
The record gives a start of Jan 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →